| TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ... Journal of clinical oncology 30 (21), 2615-2623, 2012 | 627 | 2012 |
| Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ... Cancer research 68 (3), 826-833, 2008 | 600 | 2008 |
| A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ... Cancer research 73 (15), 4885-4897, 2013 | 539 | 2013 |
| TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081-1089, 2019 | 346 | 2019 |
| Targeting HER2 for the treatment of breast cancer MF Rimawi, R Schiff, CK Osborne Annual review of medicine 66 (1), 111-128, 2015 | 335 | 2015 |
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation YC Wang, G Morrison, R Gillihan, J Guo, RM Ward, X Fu, MF Botero, ... Breast Cancer Research 13, 1-19, 2011 | 323 | 2011 |
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2 … B Dave, I Migliaccio, MC Gutierrez, MF Wu, GC Chamness, H Wong, ... Journal of clinical oncology 29 (2), 166-173, 2011 | 294 | 2011 |
| Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 … MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ... Journal of clinical oncology 31 (14), 1726-1731, 2013 | 293 | 2013 |
| Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial J Nangia, T Wang, C Osborne, P Niravath, K Otte, S Papish, F Holmes, ... Jama 317 (6), 596-605, 2017 | 280 | 2017 |
| Towards personalized treatment for early stage HER2-positive breast cancer K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ... Nature Reviews Clinical Oncology 17 (4), 233-250, 2020 | 275 | 2020 |
| Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ... Breast cancer research and treatment 136, 795-804, 2012 | 266 | 2012 |
| Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes MF Rimawi, PB Shetty, HL Weiss, R Schiff, CK Osborne, GC Chamness, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 261 | 2010 |
| Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial S Aebi, S Gelber, SJ Anderson, I Láng, A Robidoux, M Martín, ... The lancet oncology 15 (2), 156-163, 2014 | 234 | 2014 |
| Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ... Journal of the National Cancer Institute 99 (9), 694-705, 2007 | 234 | 2007 |
| First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or … M Rimawi, JM Ferrero, J de la Haba-Rodriguez, C Poole, S De Placido, ... Journal of Clinical Oncology 36 (28), 2826-2835, 2018 | 226 | 2018 |
| Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ... Journal of Clinical Oncology 37 (3), 178-189, 2019 | 207 | 2019 |
| β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib C Huang, CC Park, SG Hilsenbeck, R Ward, MF Rimawi, Y Wang, J Shou, ... Breast cancer research 13, 1-15, 2011 | 205 | 2011 |
| Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor–positive, HER-2/neu-positive breast cancer S Massarweh, CK Osborne, S Jiang, AE Wakeling, M Rimawi, SK Mohsin, ... Cancer research 66 (16), 8266-8273, 2006 | 194 | 2006 |
| Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ... Cancer chemotherapy and pharmacology 56, 10-20, 2005 | 191 | 2005 |
| Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2–positive breast cancer and … RA Freedman, RS Gelman, JS Wefel, ME Melisko, KR Hess, RM Connolly, ... Journal of Clinical Oncology 34 (9), 945-952, 2016 | 177 | 2016 |
Rachel SchiffBaylor College of MedicineBestätigte E-Mail-Adresse bei bcm.edu
